RET and non-small cell lung carcinoma: RET gain-of-function mutations are implicated in malignancies such as invasive breast cancers (30–70%), pancreatic ductal adenocarcinomas (50–60%), sporadic papillary thyroid carcinomas (2.5–73%), and NSCLC (1–3%) [47].